Press Releases

Sekisui XenoTech Awarded Cryopreservation Patent, Achieves Numerous Hepatocyte Enhancements

Tuesday, May 09, 2017

Sekisui XenoTech was issued U.S. Patent No. 9,642,355 for the “CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS,” specifically related to the CryostaX® test systems, the only single-freeze pooled hepatocytes in the industry, and enhanced its catalog of hepatocyte products with increased cell yield, viability and more...

Read more

Sekisui XenoTech Adds New Dermal Subcellular Fraction Test Systems

Wednesday, February 01, 2017

Sekisui XenoTech is adding human and minipig to the company’s list of species with dermal subcellular fractions available as standard test systems for the development of safer new products. Subcellular fractions are widely used in drug discovery and preclinical drug development to evaluate the in vitro metabolism of new therapeutics.

Read more

Sekisui XenoTech Introduces Lysosomal Test Systems for Biopharmaceutical Development

Wednesday, October 05, 2016

Hepatic human lysosomes and rat tritosomes are now available as standard test systems. These products contain high concentrations of lysosomal degradative enzymes and constitute advantageous test systems for analysis of catabolism and/or activation for targeted biopharmaceuticals that enter cells through the endosomal-lysosomal pathway...

Read more

Sekisui XenoTech Expands Hepatotoxicity Testing Services

Wednesday, August 03, 2016

Adds Assays, Methodologies to Prevent Failure of New Drugs from Liver Injury...

Read more

Sekisui XenoTech Introduces New Research BioBank

Monday, June 13, 2016

As part of Sekisui XenoTech’s commitment to furthering knowledge of hepatic diseases, the company has begun providing disease-diagnosed tissue samples and hepatocytes through its new Research BioBank.

Read more

XenoTech Provides Genotyped Hepatocytes for Polymorphic Enzyme Drug Metabolism Studies

Tuesday, April 12, 2016

Geneknown™ hepatocytes are genotyped cryopreserved human hepatocytes pooled to study the effects of specific genetic variants on drug metabolism and transport to identify risks of adverse drug interactions present only in genetically-defined subpopulations of patients. Genetically determined transport and metabolism polymorphisms have been recognized by the FDA as having potential safety and efficacy implications. This is particularly important for poor metabolizers in cases of drugs metabolized predominantly by polymorphically expressed enzymes.

Read more

XenoTech Accepting Global Scientific Achievement Award Nominations for 2015

Monday, May 18, 2015

XenoTech is accepting nominations for the 2015 Global Scientific Achievement Award, presented annually in recognition of meritorious, scientific contribution and achievement to further research in the field of ADME / DMPK. The recipient will be recognized at an upcoming industry event and will receive an honorarium, travel support, complimentary meeting registration and a $1,000 donation in their name.

Read more

XenoTech Provides Pooled Human Liver Homogenate for Evaluation of Drug Metabolizing Enzymes and Proteins

Tuesday, April 28, 2015

Sekisui XenoTech now offers pooled human liver homogenate. This test system is ideal for metabolism identification when responsible enzymes are not known, proteomic assays, enzymatic activity studies, etc.

Read more

XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014

Tuesday, April 21, 2015

Contract Research Organization, XenoTech, plans move into new global headquarters and expansion of service offerings after experiencing sizable revenue growth in 2014.

Read more

Case Study: XenoTech Ensures Quality

Monday, April 20, 2015

One company's path to accurate, reliable data in drug discovery: When your lab is one of the last stops before a compound goes into human trials, data quality is vital. Despite increasing throughput and more demanding timelines, one CRO delivers quality - consistently.

Read more

XenoTech Scientists Solve Long-Standing Mystery in Drug Metabolism

Wednesday, January 21, 2015

XenoTech has published a new scientific paper in Drug Metabolism & Disposition that solves the long-standing mystery regarding the lack of in vitro formation in classical test systems and the enzymes responsible for the formation of 3-hydroxydesloratadine, a major active human metabolite of loratadine (Claritin).

Read more

XenoTech Teams Up with JCRB to Provide Access to Over 1,100 Cell Lines in North America

Wednesday, January 07, 2015

XenoTech and the National Institute of Biomedical Innovation have teamed up to bring over 1,100 unique cell lines to the North American market.

Read more

XenoTech Receives US Patent for Its Novel Approach to Evaluate Therapeutic Proteins as Immune Modulators of Drug Metabolism

Tuesday, December 09, 2014

XenoTech has been awarded US patent # 8,846,576 “In Vitro Test System to Evaluate Xenobiotics as Immune-Modulators of Drug Transport and Metabolism in Human Hepatocytes”

Read more

Joint XenoTech / Provectus Article Published by Xenobiotica

Monday, January 27, 2014

XenoTech Aides In Provectus PV-10 Assessment for Drug-Drug Interaction Potential, Published in Xenobiotica

Read more

XenoTech Announces the Transporter Certification™ of Two Lots of Human Cryopreserved Hepatocytes by Qualyst Transporter Solutions

Wednesday, October 02, 2013

Qualyst Transporter Solutions completed the Transporter Certified™ program using two lots of high quality cryoplateable human hepatocytes from XenoTech.

Read more
Contact Us

Contact Us

Questions or inquiries? Use our contact form and we’ll reply as soon as possible.* indicates required field